We are pleased to announce our participation in the RNA Leaders Europe Congress, taking place from March 4th (Tuesday) to 6th (Thursday), 2025, at the Congress Center Basel in Basel, Switzerland. As a key exhibitor, we will also deliver an insightful oral presentation.
We warmly invite you to visit our booth and join the presentation to explore our latest advancements and innovative solutions in RNA-based technologies.

【Event details】
　Official website: RNA Therapeutics & Vaccines | RNA Leaders Europe
【Booth information】
Date: March 4th (Wed) -6th (Thu), 2025
Venue: Congress Center Basel, in Basel, Switzerland, Booth1
Access: Messe and Congress Center Basel | Event venue in the heart of the city

【Presentation title】
The strategy to establish potential and safe mRNA-based therapeutics.
Akiko Yanagiya – ARCALIS | RNA Leaders Europe Speaker
【Abstract】
ARCALIS, Inc, is the CDMO to manufacture mRNA medicine utilized for cancer vaccines and rare diseases along with infectious disease vaccines, providing our customers with seamless services from mRNA design to large-scale manufacturing. Our commercial production of self-amplifying mRNA (saRNA) as COVID-19 vaccine was initiated in 2024 at our drug substance facility. In this presentation, the strategy to establish potential and safe mRNA-based therapeutics will be presented in terms of nucleotide sequence optimization, minimization of undesirable dsRNA, mRNA-LNP formulation and our commercial manufacturing of saRNA.